Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
163 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thrombocytopenia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombocytopenia - Pipeline Review, H2 2016, provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape. Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and gums, bruising, nosebleeds and rashes. Treatment includes transfusion of platelets to stop or prevent bleeding. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombocytopenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombocytopenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Thrombocytopenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 10, 6, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Thrombocytopenia. Thrombocytopenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombocytopenia (Hematological Disorders). - The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Thrombocytopenia Overview 8 Therapeutics Development 9 Pipeline Products for Thrombocytopenia - Overview 9 Pipeline Products for Thrombocytopenia - Comparative Analysis 10 Thrombocytopenia - Therapeutics under Development by Companies 11 Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 13 Thrombocytopenia - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Thrombocytopenia - Products under Development by Companies 17 Thrombocytopenia - Products under Investigation by Universities/Institutes 20 Thrombocytopenia - Companies Involved in Therapeutics Development 21 3SBio Inc. 21 AkaRx Inc 22 Amarillo Biosciences, Inc. 23 Amgen Inc. 24 arGEN-X BV 25 BioLineRx, Ltd. 26 Biotest AG 27 Boehringer Ingelheim GmbH 28 Bolder Biotechnology, Inc. 29 Bristol-Myers Squibb Company 30 Cellerant Therapeutics, Inc. 31 Genosco 32 Hansa Medical AB 33 Immunomedics, Inc. 34 Intas Pharmaceuticals Ltd. 35 Jiangsu Hengrui Medicine Co., Ltd. 36 Merck & Co., Inc. 37 Momenta Pharmaceuticals, Inc. 38 Myelo Therapeutics GmbH 39 Neumedicines Inc. 40 Novartis AG 41 Pfizer Inc. 42 PhytoHealth Corporation 43 Prophylix Pharma AS 44 Protalex, Inc. 45 Rigel Pharmaceuticals, Inc. 46 Shionogi & Co., Ltd. 47 Shire Plc 48 STATegics, Inc. 49 UCB SA 50 ViroMed Co Ltd 51 Thrombocytopenia - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Target 53 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 61 ARGX-113 - Drug Profile 62 avatrombopag - Drug Profile 64 BBT-059 - Drug Profile 66 BI-655064 - Drug Profile 67 BL-8040 - Drug Profile 69 BMS-986004 - Drug Profile 80 BT-595 - Drug Profile 81 CLT-009 - Drug Profile 82 eltrombopag olamine - Drug Profile 83 eltrombopag olamine - Drug Profile 89 fostamatinib disodium - Drug Profile 90 GL-2045 - Drug Profile 96 GSK-2285921 - Drug Profile 97 Hetrombopag Olamine - Drug Profile 99 interferon alfa - Drug Profile 100 lusutrombopag - Drug Profile 102 M-281 - Drug Profile 103 MK-8723 - Drug Profile 104 Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile 105 Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 106 Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 107 Myelo-001 - Drug Profile 108 NMIL-121 - Drug Profile 109 Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile 112 PEG-VM501 - Drug Profile 113 PHN-013 - Drug Profile 114 PRTX-100 - Drug Profile 115 Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 122 romiplostim - Drug Profile 123 romiplostim biosimilar - Drug Profile 126 SHP-652 - Drug Profile 127 SKIO-703 - Drug Profile 130 Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 131 Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile 132 STST-4 - Drug Profile 133 thrombopoietin - Drug Profile 134 Tromplate - Drug Profile 135 TXA-302 - Drug Profile 136 UCB-7665 - Drug Profile 137 veltuzumab - Drug Profile 138 Thrombocytopenia - Dormant Projects 142 Thrombocytopenia - Discontinued Products 145 Thrombocytopenia - Product Development Milestones 146 Featured News & Press Releases 146 Appendix 159 Methodology 159 Coverage 159 Secondary Research 159 Primary Research 159 Expert Panel Validation 159 Contact Us 159 Disclaimer 160
List of Tables
Number of Products under Development for Thrombocytopenia, H2 2016 12 Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Development by Companies, H2 2016 (Contd..2) 22 Products under Investigation by Universities/Institutes, H2 2016 23 Thrombocytopenia - Pipeline by 3SBio Inc., H2 2016 24 Thrombocytopenia - Pipeline by AkaRx Inc, H2 2016 25 Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2016 26 Thrombocytopenia - Pipeline by Amgen Inc., H2 2016 27 Thrombocytopenia - Pipeline by arGEN-X BV, H2 2016 28 Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2016 29 Thrombocytopenia - Pipeline by Biotest AG, H2 2016 30 Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 31 Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2016 32 Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2016 33 Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016 34 Thrombocytopenia - Pipeline by Genosco, H2 2016 35 Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2016 36 Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2016 37 Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 38 Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39 Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2016 40 Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 41 Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2016 42 Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2016 43 Thrombocytopenia - Pipeline by Novartis AG, H2 2016 44 Thrombocytopenia - Pipeline by Pfizer Inc., H2 2016 45 Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2016 46 Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2016 47 Thrombocytopenia - Pipeline by Protalex, Inc., H2 2016 48 Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 49 Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2016 50 Thrombocytopenia - Pipeline by Shire Plc, H2 2016 51 Thrombocytopenia - Pipeline by STATegics, Inc., H2 2016 52 Thrombocytopenia - Pipeline by UCB SA, H2 2016 53 Thrombocytopenia - Pipeline by ViroMed Co Ltd, H2 2016 54 Assessment by Monotherapy Products, H2 2016 55 Number of Products by Stage and Target, H2 2016 57 Number of Products by Stage and Mechanism of Action, H2 2016 59 Number of Products by Stage and Route of Administration, H2 2016 61 Number of Products by Stage and Molecule Type, H2 2016 63 Thrombocytopenia - Dormant Projects, H2 2016 145 Thrombocytopenia - Dormant Projects (Contd..1), H2 2016 146 Thrombocytopenia - Dormant Projects (Contd..2), H2 2016 147 Thrombocytopenia - Discontinued Products, H2 2016 148
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
